Cargando…
Correction to: Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials)
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer US
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8496673/ https://www.ncbi.nlm.nih.gov/pubmed/33423216 http://dx.doi.org/10.1007/s10803-020-04822-8 |
| _version_ | 1784579803394867200 |
|---|---|
| author | Crutel, Véronique Lambert, Estelle Penelaud, Pierre-François Albarrán Severo, Cristina Fuentes, Joaquin Rosier, Antoine Hervás, Amaia Marret, Stéphane Oliveira, Guiomar Parellada, Mara Kyaga, Simon Gouttefangeas, Sylvie Bertrand, Marianne Ravel, Denis Falissard, Bruno |
| author_facet | Crutel, Véronique Lambert, Estelle Penelaud, Pierre-François Albarrán Severo, Cristina Fuentes, Joaquin Rosier, Antoine Hervás, Amaia Marret, Stéphane Oliveira, Guiomar Parellada, Mara Kyaga, Simon Gouttefangeas, Sylvie Bertrand, Marianne Ravel, Denis Falissard, Bruno |
| author_sort | Crutel, Véronique |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8496673 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Springer US |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-84966732021-10-19 Correction to: Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials) Crutel, Véronique Lambert, Estelle Penelaud, Pierre-François Albarrán Severo, Cristina Fuentes, Joaquin Rosier, Antoine Hervás, Amaia Marret, Stéphane Oliveira, Guiomar Parellada, Mara Kyaga, Simon Gouttefangeas, Sylvie Bertrand, Marianne Ravel, Denis Falissard, Bruno J Autism Dev Disord Correction Springer US 2021-01-09 2021 /pmc/articles/PMC8496673/ /pubmed/33423216 http://dx.doi.org/10.1007/s10803-020-04822-8 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Correction Crutel, Véronique Lambert, Estelle Penelaud, Pierre-François Albarrán Severo, Cristina Fuentes, Joaquin Rosier, Antoine Hervás, Amaia Marret, Stéphane Oliveira, Guiomar Parellada, Mara Kyaga, Simon Gouttefangeas, Sylvie Bertrand, Marianne Ravel, Denis Falissard, Bruno Correction to: Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials) |
| title | Correction to: Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials) |
| title_full | Correction to: Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials) |
| title_fullStr | Correction to: Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials) |
| title_full_unstemmed | Correction to: Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials) |
| title_short | Correction to: Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials) |
| title_sort | correction to: bumetanide oral liquid formulation for the treatment of children and adolescents with autism spectrum disorder: design of two phase iii studies (sign trials) |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8496673/ https://www.ncbi.nlm.nih.gov/pubmed/33423216 http://dx.doi.org/10.1007/s10803-020-04822-8 |
| work_keys_str_mv | AT crutelveronique correctiontobumetanideoralliquidformulationforthetreatmentofchildrenandadolescentswithautismspectrumdisorderdesignoftwophaseiiistudiessigntrials AT lambertestelle correctiontobumetanideoralliquidformulationforthetreatmentofchildrenandadolescentswithautismspectrumdisorderdesignoftwophaseiiistudiessigntrials AT penelaudpierrefrancois correctiontobumetanideoralliquidformulationforthetreatmentofchildrenandadolescentswithautismspectrumdisorderdesignoftwophaseiiistudiessigntrials AT albarranseverocristina correctiontobumetanideoralliquidformulationforthetreatmentofchildrenandadolescentswithautismspectrumdisorderdesignoftwophaseiiistudiessigntrials AT fuentesjoaquin correctiontobumetanideoralliquidformulationforthetreatmentofchildrenandadolescentswithautismspectrumdisorderdesignoftwophaseiiistudiessigntrials AT rosierantoine correctiontobumetanideoralliquidformulationforthetreatmentofchildrenandadolescentswithautismspectrumdisorderdesignoftwophaseiiistudiessigntrials AT hervasamaia correctiontobumetanideoralliquidformulationforthetreatmentofchildrenandadolescentswithautismspectrumdisorderdesignoftwophaseiiistudiessigntrials AT marretstephane correctiontobumetanideoralliquidformulationforthetreatmentofchildrenandadolescentswithautismspectrumdisorderdesignoftwophaseiiistudiessigntrials AT oliveiraguiomar correctiontobumetanideoralliquidformulationforthetreatmentofchildrenandadolescentswithautismspectrumdisorderdesignoftwophaseiiistudiessigntrials AT parelladamara correctiontobumetanideoralliquidformulationforthetreatmentofchildrenandadolescentswithautismspectrumdisorderdesignoftwophaseiiistudiessigntrials AT kyagasimon correctiontobumetanideoralliquidformulationforthetreatmentofchildrenandadolescentswithautismspectrumdisorderdesignoftwophaseiiistudiessigntrials AT gouttefangeassylvie correctiontobumetanideoralliquidformulationforthetreatmentofchildrenandadolescentswithautismspectrumdisorderdesignoftwophaseiiistudiessigntrials AT bertrandmarianne correctiontobumetanideoralliquidformulationforthetreatmentofchildrenandadolescentswithautismspectrumdisorderdesignoftwophaseiiistudiessigntrials AT raveldenis correctiontobumetanideoralliquidformulationforthetreatmentofchildrenandadolescentswithautismspectrumdisorderdesignoftwophaseiiistudiessigntrials AT falissardbruno correctiontobumetanideoralliquidformulationforthetreatmentofchildrenandadolescentswithautismspectrumdisorderdesignoftwophaseiiistudiessigntrials |